<DOC>
	<DOCNO>NCT02117635</DOCNO>
	<brief_summary>The primary aim Phase II trial determine whether sufficiently likely CTX DP treatment dose level 20 million cell improve recovery use paretic arm acute stroke patient justify subsequent large prospectively control study . This study evaluate safety efficacy intracerebral CTX DP dose level 20 million cell patient paresis arm follow ischaemic middle cerebral artery ( MCA ) stoke . Eligible patient useful function paretic arm minimum 28 day ischaemic stroke ( modify NIH Stroke Scale ( NIHSS ) Motor Arm Score 2 , 3 4 affected arm ) .</brief_summary>
	<brief_title>Pilot Investigation Stem Cells Stroke Phase II Efficacy</brief_title>
	<detailed_description>Design : This Phase II efficacy trial multi-centre , open label , single arm , non-comparative design , administer single dose CTX cell 2 3 month post-ischaemic stroke follow-up 12 month . The trial overseen independent DSMB . The DSMB adjudicate predetermine interval whether patient satisfy primary response criterion whether ongoing safety profile justifies continuation modification study . At least 21 patient enrol receive CTX DP ( 20 million cell ) stereotaxic intra-striatal injection ipsilateral location MCA ischaemic stroke . Pre-treatment selection patient : Men woman , age 40 , supratentorial ischaemic stroke stroke element area perfuse MCA ( i.e . stroke due ischaemia result infarct locate basal ganglion , internal capsule , corona radiata stroke due ischaemia result infarction part cerebral cortex ) . Patients first stroke within past 4 week ( time consent ) satisfy follow criterion : Modified NIHSS Motor Arm Score 2 ( effort gravity ) , 3 ( movement gravity ) 4 ( movement ) paretic arm post ischaemic stroke ; Clinical diagnosis stroke confirm physician use neuro-imaging ( computerised tomography magnetic resonance imaging ) . A Score 0 1 test 2 ARAT visit 1 2 use affected arm . Treatment : One patient treat one time . A single dose ( 20 million ) CTX DP cell administer intracranially via stereotaxic neurosurgery . Post-treatment follow-up : Patients follow 12 month post-implantation . End-points : The primary endpoint trial efficacy , use ARAT . Secondary endpoint efficacy safety . Outcome measure efficacy include Fugl-Meyer , NIHSS , BI RFA . Safety assess incidence relevant adverse event monitor patient 's general physical condition clinical measure ( temperature , pulse rate rhythm , ECG , blood pressure , full blood count , liver function test , serum urea electrolyte ) , immunological response concomitant medication 7 follow-up visit clinic first year treatment . Post-trial follow-up : Annual correspondence family practitioner ; Life-long follow-up new diagnosis cancer , site primary tumour , survival via National Cancer Registry .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Written inform consent witness informed consent event patient unable sign inform consent due paresis affect arm . Supratenorial ishaemic stroke Male female age 40 year . Stroke , time consent , satisfy follow criterion : Modified NIHSS Motor Arm Score 2 , 3 4 affected arm visit 1 visit 2 . Clinical diagnosis stroke confirm physician use neuroimaging ( CT MRI ) . A Score 0 1 test 2 ARAT day 28+7 day 56+7 poststroke use affected arm . Ability comprehend verbal command . Eligible neurosurgery include appropriate anatomical target cell implantation . Exclusion criterion : Prior history stroke result permanent moderate severe disability ( i.e . Rankin Scale great 2 ) ( present ischaemic stroke ) . Stroke due haemorrhage . History neurological disease result significant functional impairment paretic arm impair potential ability pick , lift place 2.5 cm3 block ( e.g . Parkinson 's disease , motor neuron disease , arthritis , Dupuytren 's contracture fix anatomical abnormality ) . Any contraindication MRI include presence cardiac pacemaker ( exclude MRconditional cardiac pacemaker ) , metal fragment eye etc . Uncontrolled blood pressure define systolic blood pressure ≥180 mm Hg diastolic blood pressure ≥110 mm Hg ( patient exclude initial value exceed limit repeat retesting several day ) . Patient severe comorbid disorder , expect survive 12 month . Acute cardiovascular event present ischaemic stroke ( e.g . myocardial infarction , recent coronary intervention symptomatic cardiac disease ) consider Investigator anaesthetist responsible patient place patient increase anaesthetic risk , 3 month prior plan injection CTX0E03 DP . History malignant disease ( except nonmelanoma skin cancer ) within previous 5 year history malignant brain tumour brain metastasis . Current treatment tamoxifen . Patients take valproate drug indication consider appropriate discontinue valproate period one week prior four week post neurosurgery . Patients valproate switch alternative agent period may include . Requirement antiplatelets and/or anticoagulant include heparin , warfarin anticoagulants/ medication interrupt allow surgery . Requirement intermittent ( stop/start date 1month priorto 3 month post CTX0E03 DP administration ) use oral antispasticity medication ( oral antispasticity medication acceptable take regularly least one month prior CTX0E03 DP administration ) . A history uncontrolled diabetes e.g . history hypoglycaemic hyperglycaemic event require hospital admission previous 6 month . Females childbearing potential ( FOCBP ) ( within 2 year last menstrual cycle ) must confirm negative pregnancy test time treatment agree use two reliable method contraception ( e.g . oral contraceptive condom , intrauterine device ( IUD ) condom , diaphragm spermicide condom ) duration study Sexually active male partner FOCBP must willing use reliable method contraception ( e.g . barrier spermicide describe ) duration study . Considered unlikely able attend followup visit . Organ transplant recipient In opinion investigator , sustain consumption alcohol drug level likely injurious health .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Non comparative</keyword>
	<keyword>Neural stem cell</keyword>
	<keyword>Intracranial administration</keyword>
</DOC>